Get the Stockscreener App
156.90
0.51%
-0.80
After Hours:
158.29
1.39
+0.89%
Overview
News
Price History
Option Chain
Why AZN Down?
Discussions
Forecast
Stock Split
Dividend History
Astrazeneca Plc stock is traded at $156.90, with a volume of 2.64M.
It is down -0.51% in the last 24 hours and down -2.93% over the past month.
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
See More
Previous Close:
$157.70
Open:
$158.46
24h Volume:
2.64M
Relative Volume:
0.79
Market Cap:
$243.34B
Revenue:
$60.48B
Net Income/Loss:
$10.40B
P/E Ratio:
47.12
EPS:
3.3297
Net Cash Flow:
$8.05B
1W Performance:
-5.81%
1M Performance:
-2.93%
6M Performance:
-22.90%
1Y Performance:
+87.57%
1-Day Range:
$156.41
$158.79
1-Week Range:
$156.41
$167.52
52-Week Range:
$80.48
$212.71
Astrazeneca Plc Stock (AZN) Company Profile
Name
Astrazeneca Plc
Sector
Industry
Phone
-
Address
-
Compare AZN vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AZN
Astrazeneca Plc
|
156.90 | 258.35B | 60.48B | 10.40B | 8.05B | 3.3297 |
LLY
Lilly Eli Co
|
1,142.85 | 1.02T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.03 | 623.34B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
262.82 | 459.33B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.30 | 354.80B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
141.00 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Astrazeneca Plc Stock (AZN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Initiated | Citigroup | Buy |
| Oct-27-25 | Resumed | Jefferies | Buy |
| Oct-16-25 | Downgrade | Deutsche Bank | Hold → Sell |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Feb-13-25 | Upgrade | UBS | Neutral → Buy |
| Feb-12-25 | Initiated | Morgan Stanley | Overweight |
| Nov-20-24 | Upgrade | UBS | Sell → Neutral |
| Nov-06-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Sep-13-24 | Downgrade | Deutsche Bank | Hold → Sell |
| May-30-24 | Initiated | Goldman | Buy |
| Apr-16-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Feb-08-24 | Downgrade | Deutsche Bank | Hold → Sell |
| Jan-23-24 | Initiated | Morgan Stanley | Overweight |
| Jan-16-24 | Resumed | UBS | Sell |
| Jan-03-24 | Downgrade | Jefferies | Buy → Hold |
| Dec-18-23 | Initiated | HSBC Securities | Buy |
| Sep-25-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jul-12-23 | Upgrade | UBS | Neutral → Buy |
| Jul-05-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Apr-11-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-05-23 | Initiated | BMO Capital Markets | Outperform |
| Sep-15-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Sep-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-29-22 | Upgrade | Argus | Hold → Buy |
| Jun-14-22 | Downgrade | UBS | Buy → Neutral |
| Feb-11-22 | Upgrade | DZ Bank | Sell → Hold |
| Dec-07-21 | Downgrade | Jefferies | Buy → Hold |
| Aug-12-21 | Resumed | JP Morgan | Overweight |
| Apr-12-21 | Downgrade | Argus | Buy → Hold |
| Mar-16-21 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Upgrade | UBS | Neutral → Buy |
| Jan-15-21 | Initiated | Deutsche Bank | Buy |
| Dec-07-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-30-20 | Upgrade | UBS | Sell → Neutral |
| Nov-11-20 | Upgrade | HSBC Securities | Reduce → Hold |
| Sep-29-20 | Initiated | Berenberg | Buy |
| Nov-22-19 | Initiated | SVB Leerink | Outperform |
| Oct-25-19 | Upgrade | Liberum | Hold → Buy |
| Apr-02-19 | Downgrade | UBS | Neutral → Sell |
| Feb-05-19 | Initiated | Exane BNP Paribas | Outperform |
| Jan-25-19 | Upgrade | Shore Capital | Hold → Buy |
| Dec-11-18 | Resumed | Jefferies | Hold |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Aug-16-18 | Downgrade | Jefferies | Buy → Hold |
| Mar-19-18 | Upgrade | Jefferies | Hold → Buy |
| Feb-06-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-05-18 | Reiterated | Bernstein | Outperform |
| Jan-18-18 | Reiterated | Leerink Partners | Mkt Perform |
| Dec-29-17 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-16-17 | Upgrade | Credit Suisse | Neutral → Outperform |
| Sep-25-17 | Upgrade | Exane BNP Paribas | Neutral → Outperform |
| Sep-22-17 | Upgrade | Bernstein | Mkt Perform → Outperform |
View All
Astrazeneca Plc Stock (AZN) Latest News
AstraZeneca stock after-hours at EUR 141.75: minus 1.05 percent versus prior close - AD HOC NEWS
Employee schemes bring 9,828 new AstraZeneca (AZN) shares to London Stock Exchange trading. - Stock Titan
With no treasury shares, AstraZeneca (AZN) reports 1.55B voting rights. - Stock Titan
AstraZeneca Adds Employee Scheme Shares to London Listing - TipRanks
REGAstraZeneca PLCAdmission of Further Securities to Trading - TradingView
DaltonTx, the decision engine for drug discovery, launches advanced AI-powered antibody discovery platform - GlobeNewswire Inc.
AstraZeneca invests USD 2 billion in Summit. AstraZeneca stock falls 1.24 percent. - AD HOC NEWS
AstraZeneca (LSE:AZN) Oncology Filing Puts Valuation and Growth Back in Focus - kalkinemedia.com
700,000 Seniors Have Started GLP-1s Through Medicare. Now AstraZeneca Just Moved a Once-Daily Pill Into Phase 3 - Yahoo Finance
AstraZeneca slips Wednesday, underperforms market - MarketWatch
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets - 247wallst.com
AstraZeneca PLC Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – AZN - ACCESS Newswire
AstraZeneca PLC : Deutsche Bank reaffirms its Neutral rating - marketscreener.com
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast - GlobeNewswire Inc.
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up - reuters.com
AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination - reuters.com
AstraZeneca PLC (AZN) Stock Down 1.2% -- Now Undervalued? GF Sco - GuruFocus
Astrazeneca (AZN) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance Singapore
A $2 Billion Reason Why AstraZeneca Stock Is Down Today - Barchart.com
AstraZeneca submits NDA for savolitinib + Tagrisso for NSCLC - Seeking Alpha
AstraZeneca pours $2bn into Summit to advance cancer treatment - BioXconomy
Summit Shares Jump on $2B Strategic Investment From AstraZeneca - TradingView
AstraZeneca Invests in Summit Therapeutics after Year of Speculation - Benzinga
AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push - BioPharma Dive
AstraZeneca’s $2 billion Summit stake wins backing from UBS and Jefferies - Proactive financial news
Summit Secures $2 Billion AstraZeneca Investment, Cancer Drug Trial Collaboration - marketscreener.com
Summit Therapeutics Soars Nearly 20% After AstraZeneca Bets $2 Billion on Cancer Drug Ivonescimab - Benzinga
Goldman Sachs reiterates Summit Therapeutics stock rating on AstraZeneca deal - Investing.com
Rights equivalent to a 12% stake await closing as AstraZeneca (AZN) agrees to invest in Summit. - Stock Titan
AstraZeneca to invest $2bn in Summit for ADC combination therapies - Pharmaceutical Technology
Summit soars after $2 billion investment from AstraZeneca for cancer therapies - reuters.com
AstraZeneca PLC : RBC reaffirms its Buy rating - marketscreener.com
AstraZeneca PLC : JP Morgan maintains a Buy rating - marketscreener.com
AstraZeneca invests $2bn in Summit Therapeutics - marketscreener.com
FTSE 100 rises as AstraZeneca lifts healthcare sector - marketscreener.com
AstraZeneca PLC : Deutsche Bank is Neutral - marketscreener.com
AstraZeneca invests £1.5bn into US firm Summit for cancer drug tie-up - uk.finance.yahoo.com
Analysts back AstraZeneca's $2B Summit Therapeutics investment as stock gains (AZN:NYSE) - Seeking Alpha
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal - Proactive financial news
AstraZeneca takes $2bn stake in Summit Therapeutics to pair up cancer drugs - Proactive Investors
AstraZeneca Invests $2bn In Summit To Accelerate Ivonescimab Development - DirectorsTalk Interviews
AstraZeneca to Buy $2 Billion of New Equity in Summit Therapeutics - marketscreener.com
AstraZeneca PLC submits US NDA for Orpathys plus Tagrisso - Mugglehead Investment Magazine
Summit Therapeutics agrees to US$2B AstraZeneca equity investment - Mugglehead Investment Magazine
AstraZeneca files US FDA application for Hutchmed lung cancer drug combination - marketscreener.com
SMMT Stock Soars After-Hours: Did AstraZeneca Just End Summit’s Cash Scare? - Yahoo Finance
AstraZeneca (AZN) is Expanding its Oncology Engine. Can New Growth Offset Legacy Pressure? - Yahoo Finance
Summit Therapeutics Shares Jump as AstraZeneca's Plan to Invest $2 Billion - marketscreener.com
AstraZeneca to invest USD2 billion in Summit Therapeutics - marketscreener.com
Summit shares surge after-hours on $2 billion AstraZeneca equity deal - Yahoo Finance
AstraZeneca Invests $2 Billion in Summit Therapeutics; Enters Clinical Collaboration - marketscreener.com
Astrazeneca Plc Stock (AZN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):